Panbela Therapeutics (NASDAQ:PBLA) Shares Down 9.1% – Time to Sell?

Panbela Therapeutics, Inc. (NASDAQ:PBLA)’s share price was down 9.1% during mid-day trading on Friday . The company traded as low as $0.39 and last traded at $0.41. Approximately 2,947 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 27,623 shares. The stock had previously closed at $0.45.

Panbela Therapeutics Stock Performance

The company’s fifty day moving average price is $0.34 and its 200 day moving average price is $0.35. The firm has a market capitalization of $1.99 million, a price-to-earnings ratio of -0.01 and a beta of 1.56.

Panbela Therapeutics Company Profile

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.